H.C. Wainwright analyst Mitchell Kapoor has reiterated their bullish stance on NTLA stock, giving a Buy rating on June 13.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Mitchell Kapoor’s rating is based on the promising three-year data for Intellia Therapeutics’ gene editing therapy, NTLA-2002, which demonstrated a significant reduction in hereditary angioedema (HAE) attack rates. The data showed that a single dose led to a 98% mean reduction in monthly HAE attacks, with patients remaining attack-free and treatment-free for a median of 23 months. This suggests a durable efficacy that is crucial for risk mitigation as the company moves towards Phase 3 trials.
Furthermore, the study highlighted dose-dependent effects, with the highest dose achieving a nearly 95% reduction in plasma kallikrein levels, indicating strong and sustained efficacy. The safety profile was also favorable, with only transient and mild adverse events reported, and no long-term risks identified. These factors collectively support the Buy rating, along with a 12-month price target of $30 per share, reflecting confidence in the therapy’s potential and the company’s future prospects.
In another report released on June 13, Wells Fargo also maintained a Buy rating on the stock with a $50.00 price target.